Endo's $1.6bn Paladin buy will boost generic-challenged revenue
This article was originally published in Scrip
Executive Summary
Endo Health Solutions will acquire Paladin Labs in a nearly all-stock $1.6bn deal that will immediately contribute to Endo's income when the deal closes next year, giving the Malvern, Pennsylvania-based company a needed boost in pharmaceutical revenue, which has taken a hit from new generic competition.